AVITA Medical (ASX:AVH) Altman Z-Score: -12.48 (As of Jun. 26, 2026)


ASX:AVH AVITA Medical Inc ASX:AVH
57 GF Score
Price A$1.09
GF Value A$3.05
Valuation Possible Value Trap
! 6 Warning Signs
View Full Analysis

What is AVITA Medical Altman Z-Score?

AVITA Medical ASX:AVH -2.25% 57 Altman Z-Score is -12.48 as of Jun. 26, 2026. GuruFocus rates ASX:AVH with a GF Score™ of 57/100 and a GF Value™ of A$3.05 (Possible Value Trap). The stock has 6 warning signs investors should review. Among 809 Medical Devices & Instruments companies, AVITA Medical ranks worse than 93.57% on this metric.

The Altman Z-Score is a model designed to predict the likelihood of a company going bankrupt within the next two years. Created by American finance professor Edward Altman in 1968, the model is specifically designed for publicly traded manufacturing companies with assets greater than $1 million.

Warning Sign:

Altman Z-score of -12.39 is in distress zone. This implies bankruptcy possibility in the next two years.

AVITA Medical has a Altman Z-Score of -12.48, indicating it is in Distress Zones. This implies bankrupcy possibility in the next two years.

The zones of discrimination were as such:

When Altman Z-Score <= 1.8, it is in Distress Zones.
When Altman Z-Score >= 3, it is in Safe Zones.
When Altman Z-Score is between 1.8 and 3, it is in Grey Zones.

The historical rank and industry rank for AVITA Medical's Altman Z-Score or its related term are showing as below:

ASX:AVH' s Altman Z-Score Range Over the Past 10 Years
Min: -15.36   Med: 4.03   Max: 2016.55
Current: -12.39

During the past 13 years, AVITA Medical's highest Altman Z-Score was 2016.55. The lowest was -15.36. And the median was 4.03.


AVITA Medical  (ASX:AVH) Altman Z-Score Explanation

X1: The Working Capital/Total Assets (WC/TA) ratio is a measure of the net liquid assets of the firm relative to the total capitalization. Working capital is defined as the difference between current assets and current liabilities. Ordinarily, a firm experiencing consistent operating losses will have shrinking current assets in relation to total assets. Altman found this one proved to be the most valuable liquidity ratio comparing with the current ratio and the quick ratio. This is however the least significant of the five factors.

X2: Retained Earnings/Total Assets: the RE/TA ratio measures the leverage of a firm. Retained earnings is the account which reports the total amount of reinvested earnings and/or losses of a firm over its entire life. Those firms with high RE, relative to TA, have financed their assets through retention of profits and have not utilized as much debt.

X3, Earnings Before Interest and Taxes/Total Assets (EBIT/TA): This ratio is a measure of the true productivity of the firm's assets, independent of any tax or leverage factors. Since a firm's ultimate existence is based on the earning power of its assets, this ratio appears to be particularly appropriate for studies dealing with corporate failure. This ratio continually outperforms other profitability measures, including cash flow.

X4, Market Value of Equity/Book Value of Total Liabilities (MVE/TL): The measure shows how much the firm's assets can decline in value (measured by market value of equity plus debt) before the liabilities exceed the assets and the firm becomes insolvent.

X5, Revenue/Total Assets (S/TA): The capital-turnover ratio is a standard financial ratio illustrating the sales generating ability of the firm's assets.

Read more about Altman Z-Score and the original research.


Be Aware

Altman Z-Score does not apply to financial companies.


AVITA Medical Altman Z-Score Related Terms


AVITA Medical Altman Z-Score Historical Data

* Premium members only.

The historical data trend for AVITA Medical's Altman Z-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

AVITA Medical Altman Z-Score Chart

AVITA Medical Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Dec22 Dec23 Dec24 Dec25
Altman Z-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 29.29 4.03 0.06 -4.60 -11.13

AVITA Medical Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Altman Z-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -6.77 -9.94 -8.89 -11.13 -12.45

ASX:AVH vs NNOX, MXCT, SNWV: Altman Z-Score Comparison

For the Medical Devices subindustry, AVITA Medical's Altman Z-Score, along with its competitors' market caps and Altman Z-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


AVITA Medical Altman Z-Score vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, AVITA Medical's Altman Z-Score distribution charts can be found below:

* The bar in red indicates where AVITA Medical's Altman Z-Score falls into.


ASX:AVH
57GF Score
AVITA Medical Inc ASX:AVH
Altman Z-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

AVITA Medical Altman Z-Score Calculation

Altman Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.

AVITA Medical's Altman Z-Score for today is calculated with this formula:

Z=1.2*X1+1.4*X2+3.3*X3+0.6*X4+1.0*X5
=1.2*-0.6795+1.4*-8.1292+3.3*-0.8182+0.6*1.5683+1.0*1.4717
=-12.48

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency. GuruFocus does not calculate Altman Z-Score when X4 or X5 value is 0.

Trailing Twelve Months (TTM) ended in Mar. 2026:
Total Assets was A$73.5 Mil.
Total Current Assets was A$45.1 Mil.
Total Current Liabilities was A$95.0 Mil.
Retained Earnings was A$-597.1 Mil.
Pre-Tax Income was -15.136 + -17.515 + -19.969 + -15.231 = A$-67.9 Mil.
Interest Expense was -2.029 + -1.881 + -1.922 + -1.923 = A$-7.8 Mil.
Revenue was 27.433 + 26.511 + 25.866 + 28.29 = A$108.1 Mil.
Market Cap (Today) was A$167.0 Mil.
Total Liabilities was A$106.5 Mil.

* Note that for stock reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data.

X1=Working Capital/Total Assets
=(Total Current Assets - Total Current Liabilities)/Total Assets
=(45.097 - 95.006)/73.45
=-0.6795

X2=Retained Earnings/Total Assets
=-597.092/73.45
=-8.1292

X3=Earnings Before Interest and Taxes/Total Assets
=(Pre-Tax Income - Interest Expense)/Total Assets
=(-67.851 - -7.755)/73.45
=-0.8182

X4=Market Value Equity/Book Value of Total Liabilities
=Market Cap/Total Liabilities
=166.960/106.462
=1.5683

X5=Revenue/Total Assets
=108.1/73.45
=1.4717

The zones of discrimination were as such:

Distress Zones - 1.81 < Grey Zones < 2.99 - Safe Zones

AVITA Medical has a Altman Z-Score of -12.48 indicating it is in Distress Zones.

Study by Altman found that companies that are in Distress Zone have more than 80% of chances of bankruptcy in two years.

Frequently Asked Questions Learn more about Altman Z-Score →
What does a Altman Z-Score of -12.48 mean?
AVITA Medical (ASX:AVH) has a Altman Z-Score of -12.48 as of Jun. 26, 2026. The Altman Z-score measures a company's bankruptcy risk. View historical data on AVITA Medical and its competitors. According to the industry distribution chart, AVITA Medical ranks #757 out of 809 companies in the Medical Devices & Instruments industry, placing it in the top 93.6%.
Is AVITA Medical's Altman Z-Score too high?
AVITA Medical's current Altman Z-Score is -12.48. Based on the distribution chart, AVITA Medical ranks #757 out of 809 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, AVITA Medical has a GF Score™ of 57/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does AVITA Medical's Altman Z-Score compare to NNOX and MXCT?
According to the Medical Devices & Instruments industry distribution chart, AVITA Medical ranks #757 out of 809 companies for Altman Z-Score. This places AVITA Medical in the lower half of its industry. The industry median Altman Z-Score is 2.92. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Altman Z-Score for a Medical Devices & Instruments company?
The median Altman Z-Score among Medical Devices & Instruments companies is 2.92, based on 809 companies in the industry. Companies in the top quartile (top 25%) have a Altman Z-Score significantly above this median, while those in the bottom quartile fall well below. However, Altman Z-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Altman Z-Score mean?
A high Altman Z-Score can signal that a stock is expensive relative to its fundamentals. The Altman Z-score measures a company's bankruptcy risk. View historical data on AVITA Medical and its competitors. For the Medical Devices & Instruments industry, the median Altman Z-Score is 2.92 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. AVITA Medical's current Altman Z-Score is -12.48. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is AVITA Medical stock overvalued right now?
Based on GuruFocus' analysis, AVITA Medical (ASX:AVH) is currently considered Possible Value Trap. The stock's GF Value™ is A$3.05, compared to a current price of A$1.09 — trading 64.4% below its estimated fair value. The current Altman Z-Score is -12.48. AVITA Medical's overall GF Score™ is 57/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Altman Z-Score calculated?
Altman Z-Score is calculated from a company's financial statements. For AVITA Medical (ASX:AVH), the current Altman Z-Score is -12.48 as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is AVITA Medical (ASX:AVH) Overvalued in 2026?

Based on GuruFocus' analysis, AVITA Medical stock appears to be undervalued. The current stock price of A$1.09 is trading 64.4% below its estimated GF Value™ of A$3.05. GuruFocus considers AVITA Medical to be Possible Value Trap.

Key valuation signals for ASX:AVH:

  • Altman Z-Score: -12.48
  • GF Value™: A$3.05 vs. price of A$1.09 (64.4% below fair value)
  • GF Score™: 57/100 with 6 warning signs

No single metric tells the full story. See the ASX:AVH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


AVITA Medical Business Description

Address 28159 Avenue Stanford, Suite 220, Valencia, Santa Clarita, CA, USA, 91355
Avita is largely a single product company. Its RECELL system is an innovative burn treatment device which creates Spray-on Skin from a small skin sample within 30 minutes, thus avoiding or reducing the need for skin grafts. It's approved for the treatment of adult and paediatric patients in the US and an expanded indication for soft-tissue reconstruction. It is currently used in most of the 140 US burn centers. Despite having product approval in Australia, Canada, and China, Avita is not actively marketing in those territories and focussing instead on the US region, although international sales, particularly in Japan, are growing. Avita is domiciled, and has its primary listing, in the US.
57GF Score

Get the complete analysis for ASX:AVH

Altman Z-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$1.09
Price
A$3.05
GF Value